Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Emerging Leaders
not ranked
Current Leaders
#1172 pts
All-Time Leaders
#2187 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2017. 28 trials as lead/chair. How it works →
Trials led — by scientific impact
Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
16
impact
Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
16
impact
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
12
impact
Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
12
impact
Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
12
impact
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
12
impact
Multi-center Phase I/II Clinical Trial of Multiple CAR T Cells for Treating Acute Myeloid Leukemia
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
11
impact
Multicenter Trial of Phase I/II Studies on GD2 Positive Solid Tumors by 4SCAR-GD2
Phase 2RecruitingShenzhen Geno-Immune Medical Institute
11
impact
Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
11
impact
Multicenter Trial of Cancer Antigen-specific T Cells in the Treatment of Lung Cancer
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
10
impact
Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
9
impact
Direct Lentiviral TYF-ARSA Injection Gene Therapy for Metachromatic Leukodystrophy (MLD)
N/ARecruitingShenzhen Geno-Immune Medical Institute
8
impact
Lentiviral FVIII Gene Therapy for Hemophilia A
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
7
impact
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
7
impact
CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
6
impact
Lentiviral FIX Gene Therapy for Hemophilia B
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
6
impact
Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Via Direct Intravenous Injection of Lentiviral Vector (Ivlv-X1)
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
6
impact
Gene Therapy Via Intravenous Injection of Lentiviral Vector (Ivlv-ADA) for the Treatment of Adenosine Deaminase-severe Combined Immunodeficiency (ADA-SCID)
N/ARecruitingShenzhen Geno-Immune Medical Institute
5
impact
Gene Transfer for Fanconi Anemia Using a Self-inactivating Lentiviral Vector
N/ARecruitingShenzhen Geno-Immune Medical Institute
4
impact
Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)
Phase 2RecruitingShenzhen Geno-Immune Medical Institute
2
impact
Immunogene-modified Antigen-specific T (IgT) Cells for the Treatment of Glioblastoma Multiforme
Phase 1Enrolling by InvitationShenzhen Geno-Immune Medical Institute
2
impact
Innovative Treatment of Cervical Cancer Using Engineered Antigen-specific Immune Effectors (EIEs)
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
1
impact
Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
0
impact
Immune Modulatory DC Vaccine Against Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma (GBM)
Phase 1Enrolling by InvitationShenzhen Geno-Immune Medical Institute
0
impact
Phase I/II Multicenter Trial of Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
0
impact
Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)
Phase 1RecruitingShenzhen Geno-Immune Medical Institute
0
impact
Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)
Phase 1Enrolling by InvitationShenzhen Geno-Immune Medical Institute
0
impact
Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer
Phase 1RecruitingShenzhen Geno-Immune Medical InstituteStudy Chair
0
impact
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
N/AUnknownShenzhen Geno-Immune Medical Institute
0
impact
Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)
Phase 2WithdrawnShenzhen Geno-Immune Medical Institute
0
impact